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Introduction
Prenatal screening with α-fetoprotein (AFP) and ultra-
sonography have allowed the prenatal diagnosis of neu-
ral tube defects (NTDs) in current obstetric care, and
open spina bifida has been considered a potential can-
didate for in utero treatment in modern pediatric surgery.
This article provides an overview of maternal serum
AFP screening, amniotic fluid AFP assays, amniotic fluid
acetylcholinesterase immunoassays and level II ultra-
sound for NTDs, prenatal repair of fetal myelomeningo-
cele, recurrence risk of NTDs, and differential diagnosis
of NTDs using prenatal ultrasound.
Maternal Serum AFP Screening, Amniotic
Fluid AFP Assays, Amniotic Fluid
Acetylcholinesterase Immunoassays and
Level II Ultrasound for NTDs
Maternal serum screening for open NTDs using AFP
began in the 1970s. In 1977, Wald et al [1] found that
maternal serum AFP ≥ 2.5 multiples of the median
(MoM) occurred in 88% of cases of anencephaly, 79%
of cases of open spina bifida and 3% of unaffected sin-
gleton pregnancies when tested at 16–18 gestational
weeks. Maternal serum AFP test is performed between
15 and 20 or 22 gestational weeks using the threshold
of 2.5 MoM, with an anticipated sensitivity of 85% for
NTD detection, a screen-positive rate of 5% or less and
a positive predictive value of about 2% (2% of all women
with a positive test result are carrying a fetus with an
NTD) [2–4]. The American College of Obstetricians and
Gynecologists (ACOG) [4] suggested that maternal
serum AFP elevation is an effective screening test for
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NTDs and should be offered to all pregnant women
unless they plan to have amniotic fluid AFP measure-
ments as part of the prenatal diagnosis of chromoso-
mal abnormalities or other genetic diseases. Reichler
et al [5] found that in a total of 529 patients with an
elevated maternal serum AFP level and amniocentesis,
there was a progressive increase of anomalies as a
direct function of the level of maternal AFP, varying
from 3.38% at a level of 2.5–2.9 MoM, 7.79% at a level
of 3.0–3.9 MoM, 13.11% at a level of 4.0–4.9 MoM,
18.18% at a level of 5.0–6.9 MoM to 40.28% at a level
≥ 7.0 MoM. In the study of Reichler et al [5], the risk 
of NTDs varied from 1.45% (2.5–2.9 MoM), 3.25%
(3.0–3.9 MoM), 4.92% (4.0–4.9 MoM), 10.90% (5.0–
6.9 MoM) to 13.46% (≥ 7.0 MoM). Women with ma-
ternal serum AFP levels higher than a predetermined
cutoff level (usually 2–2.5 MoM) should be referred for
genetic counseling and consideration of a diagnostic
test [4,6]. A typical NTD screening protocol has been
suggested as follows [6]:
1. If the maternal serum AFP is < 2.0 MoM, no further
action is required.
2. If the maternal serum AFP is ≥ 2.0 MoM, ultra-
sound is required to check dates.
3. Following date checking by ultrasound, if there is
a difference of < 10 days from the last menstrual
period, the screening remains positive. If there is a
difference of ≥ 10 days from the last menstrual
period and the maternal serum AFP is ≥ 2.0 MoM
after date adjustment, the screening is positive.
Genetic counseling for risks and benefits of amnio-
centesis and/or level II ultrasound should be offered
when the screening is positive.
In the case of an elevated amniotic fluid AFP level in the
presence of acetylcholinesterase, doctors should consider
a diagnosis of NTD. In a study of 9,964 women with sin-
gleton pregnancies and known outcome (including six
with anencephaly and 18 with open spina bifida), Loft
et al [7] found that the acetylcholinesterase immuno-
assays and the amniotic fluid AFP assays yielded a 100%
detection rate for anencephaly and for open spina bifida,
with a false-positive rate of 0.22% and 0.08% for the ace-
tylcholinesterase immunoassays and amniotic fluid AFP
assays, respectively. Watson et al [8] found a 0.61% risk
of chromosomal anomalies in pregnancies complicated
by an elevated maternal serum AFP level but without any
sonographically detected fetal structural abnormalities.
In contrast, Harmon et al [9] found a 16.3% risk of
chromosomal anomalies in pregnancies with prenatally
diagnosed isolated NTDs, compared with a 0.3% risk
in the same population based solely on maternal age.
With experienced sonologists, sonography is sensitive
and specific for the diagnosis of open NTDs [10–17].
In view of the increasing resolution of sonographic
equipments and the 0.5% risk of post-procedure preg-
nancy loss in second-trimester amniocentesis, the need
for amniocentesis in pregnant women with elevated levels
of maternal serum AFP but normal ultrasonographic
examination has been questioned [10,11,14,17]. Hogge
et al [10] suggested that targeted ultrasonography alone
may be a reasonable alternative for amniocentesis in
the evaluation of pregnancies at risk for NTDs. In a study
of the relative efficacy of amniocentesis versus targeted
(detailed) ultrasonography in 225 patients referred
because of an elevated maternal serum AFP level (79.6%)
or a family history of NTDs (20.4%), Hogge et al [10]
found that sonographic examination alone detected all
26 fetal anomalies, including 11 cases of anencephaly,
10 of open spina bifida and five of other anomalies.
Nadel et al [11] reviewed the ultrasound findings in 51
consecutive fetuses with spina bifida, encephalocele,
gastroschisis or omphalocele and found that all 51 cases
were correctly diagnosed. The authors suggested that
women with elevated maternal serum AFP levels should
be referred to institutions that can perform level II ultra-
sound; if the level II ultrasound is normal, the patients
can be told that the risk of an anomaly is low and can
make an informed decision about whether or not to
proceed with amniocentesis. Katz et al [12] detected all
nine open NTDs among patients with elevated maternal
serum AFP using ultrasound. The authors suggested
that informed consent prior to amniocentesis should
include a discussion of the ultrasound evaluation for
evaluation of elevated maternal serum AFP. Lennon
and Gray [13] found that ultrasound alone was 97%
sensitive and 100% specific in diagnosing open NTDs.
In a study of 4,430 cases of mid-trimester amniocentesis,
Mandruzzato et al [14] found that all 13 cases presenting
with structural malformations were correctly diagnosed
by ultrasound. The authors suggested that if there is
optional ultrasound scanning, routine assessment of
amniotic AFP at the time of mid-trimester genetic amnio-
centesis is no longer justified. Norem et al [15] retro-
spectively identified 189 NTD cases among 219,000
consecutive pregnancies and found that among the
102 NTD cases who had received maternal serum AFP
screening, 25 cases (25%) had negative maternal serum
screening results, including 15 (38%) of the 40 spina
bifida cases screened, six (67%) of the nine encephalocele
cases screened and four (8%) of the 53 anencephaly
cases screened. They additionally found that of the
186 NTD cases diagnosed prenatally, 115 (62%) were
initially detected by routine ultrasound without knowl-
edge of maternal serum AFP screening, 69 (37%) were
diagnosed by targeted ultrasound with knowledge of
elevated maternal serum AFP values and two (1%) were
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diagnosed by pathologic examination after miscarriage.
Norem et al [15] concluded that second-trimester
ultrasound was more likely to detect NTDs, with 93%
(50/54) sensitivity for the detection of spina bifida,
100% (59/59) sensitivity for the detection of anen-
cephaly, 94% (16/17) sensitivity for the detection of
encephalocele and 96% (125/130) sensitivity for the
detection of NTDs using standard ultrasound. They sug-
gested that maternal serum AFP screening should not
be the sole screening method for detecting NTDs, and
that routine second-trimester ultrasound should be
included as part of standard prenatal care. Dashe et al
[16] found that standard ultrasound improved NTD
detection over maternal serum AFP screening alone, by
improving maternal serum AFP test sensitivity from
65% to 86% if the gestational age used for AFP calcula-
tion was confirmed with ultrasound, and by identify-
ing NTDs in low-risk pregnancies with 100% sensitivity
using standard ultrasound. In a study of 6,501 women
who underwent amniocentesis and had amniotic fluid
measurements taken, Kooper et al [17] found that 27
out of 6,188 pregnancies (0.4%) without any increased
NTD risk had amniotic fluid AFP levels > 2.5 MoM,
and two of which were associated with NTDs; two out
of 258 pregnancies (0.8%) with an increased NTD risk
had an increased amniotic fluid AFP level and were
associated with NTDs; and 44 out of 55 pregnancies
(80%) with clinically diagnosed fetal NTDs had an in-
creased amniotic fluid AFP level. The authors suggested
that high-quality ultrasound imaging will accurately
detect NTDs and that fetal anomaly scan will potentially
replace routine amniotic fluid AFP testing, although
NTDs may be difficult to be detected by standard ultra-
sound in cases of maternal obesity and fetal persistent
spine posterior position.
Prenatal Repair of Fetal
Myelomeningocele
Management of Myelomeningocele Study 
(MOMS) trial
Prenatal repair of fetal myelomeningocele is an accept-
able fetal surgery but with unproven benefits [4,18,19].
The role of the prenatal repair of fetal myelomeningo-
cele is presently being investigated in the Management
of Myelomeningocele Study (MOMS) trial, which began
in February 2003, had approximately 112 patients in
March 2007 and is estimated to be completed in 2009
[19]. The MOMS trial is an unblinded, randomized, con-
trolled clinical trial of 200 patients in three institutions,
i.e. The Children’s Hospital of Philadelphia (CHOP),
Vanderbilt University Medical Center (VUMC) and the
University of California at San Francisco (UCSF), and
is sponsored by the National Institute of Child Health
and Human Development (NICHD) in the United
States [19]. The primary end-point of the trial is the
need for shunt at 1 year, and the secondary end-points
are neurologic function, cognitive outcome and mater-
nal morbidity following prenatal repair of fetal myelo-
meningocele [19]. The research agenda include reversal
of hindbrain herniation, changes in fetal posterior fossa
volume in myelomeningocele fetuses who undergo fetal
surgery and those who do not, indications for shunting
myelomeningocele patients who have ventriculomegaly
but no evidence of overt increased intracranial pressure,
and incidence of inclusion dermoid cysts in fetal sur-
gery patients and in postnatally closed patients [19].
The inclusion criteria of the trial include myelome-
ningocele at level T1–S1 with hindbrain herniation,
maternal age of 18 years or older, gestational age of
18–25 weeks at randomization, and normal karyotype
[19]. Patients are centrally randomized to one of the
following two different management protocols: (1) in-
trauterine repair of the myelomeningocele at 18–25 ges-
tational weeks and cesarean delivery at 37 gestational
weeks with lung maturity; or (2) cesarean delivery at
37 gestational weeks with lung maturity and neonatal
repair of the myelomeningocele.
“Two-hit” hypothesis
Heffez et al [20] first proposed the “two-hit” hypo-
thesis of which the first hit is the primary developmen-
tal abnormalities of NTDs, and the second hit is the
secondary spinal cord injury caused by environmental
exposures such as amniotic fluid, contact with the uter-
ine wall, and/or pressure from the birth canal. Heffez
et al [20] suggested that intrauterine protection of the
exposed spinal cord may prevent some of the paraly-
sis. In a study of eight stillborn human fetuses with
myelomeningocele, Hutchins et al [21] found that the
acquired spinal cord injury and the injury or destruction
of the dorsal spinal cord were recent and consistent
with occurrence during delivery. In a histologic study
of the myelomeningocele lesions with surrounding tis-
sues from 10 human fetuses between 19 and 23 gesta-
tional weeks, Meuli et al [22] found that the exposed
neural tissue had undergone varying degrees of recent
traumatic injury as a result of its exposed position, and
the neural tissue remaining in the myelomeningocele
contained hemorrhage and abrasions from recent in-
jury, suggesting that injury occurred during passage
through the birth canal. Drewek et al [23] found that
amniotic fluid became toxic at approximately 34 ges-
tational weeks. In a study of human myelomeningocele
placodes using immunohistochemical caudal spinal cord
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markers and structural markers, George and Cummings
[24] found abnormal patterning along the dorsoven-
tral and rostrocaudal axes, a paucity of maturing neu-
rons, and significant inflammatory infiltrate, gliosis and
fibrosis consistent with secondary injury.
Human experience with intrauterine 
myelomeningocele repair
Reversal of hindbrain herniation and need for
ventriculoperitoneal shunting
In a study of 29 patients with intrauterine myelome-
ningocele repair performed at the VUMC and 23 con-
trols, Bruner et al [25] found that intrauterine repair
decreased the incidence of hindbrain herniation (38% vs.
95%; p < 0.01) and the incidence of shunt-dependent
hydrocephalus (59% vs. 91%; p = 0.01). At VUMC,
Tulipan et al [26] found that intrauterine myelomenin-
gocele repair reversed preexisting hindbrain herniation.
In a study of 10 patients undergoing fetal myelome-
ningocele closure at CHOP, Sutton et al [27] found
that all nine surviving neonates showed improvement
in the hindbrain hernia at the 3-week postoperative
fetal scan, and only one neonate required placement of
ventriculoperitoneal shunt. In a study of 104 patients
with intrauterine myelomeningocele repair performed
at either VUMC or CHOP and 189 controls, Tulipan 
et al [28] found that intrauterine myelomeningocele
repair significantly reduced the incidence of shunt-
dependent hydrocephalus (54.8% vs. 85.7%). However,
patients with lesions above L3 did not share in this
benefit, and patients with fetal surgery at > 25 gesta-
tional weeks had a shunt rate of 75% in comparison
with 44.1% of those with fetal surgery at ≤ 25 gesta-
tional weeks. In a study of 50 fetuses with intrauterine
myelomeningocele repair performed at CHOP, Johnson
et al [29] found that all fetuses had reversal of hind-
brain herniation, and 20 of the 47 surviving fetuses
(42.6%) had required ventriculoperitoneal shunting
compared with 100% for thoracic, 88% for lumbar and
68% for sacral lesions (85% overall) in 297 historic con-
trols who underwent postnatal neurosurgical closure.
In a study of fetal head biometry by fetal magnetic res-
onance imaging in 22 patients with intrauterine myelo-
meningocele repair performed at CHOP, Danzer et al
[30] found significant reversal of hindbrain herniation
and normalization of the posterior fossa cerebrospinal
fluid (CSF) spaces when compared with the controls.
Lower extremity function and urinary bladder function
Tubbs et al [31] found no improvement in the lower
extremity function of 37 patients with intrauterine
myelomeningocele repair performed at VUMC when
compared with the controls. In a study of 50 patients
with intrauterine myelomeningocele repair performed at
CHOP, Johnson et al [29] found better-than-predicted
leg function in 57% of thoracic and lumbar level lesion
patients. However, the CHOP criteria demanded intact
leg and foot motion to be presented prior to fetal sur-
gery and only included early-gestation (≤ 26 gestational
weeks) repair. Holzbeierlein et al [32] studied the uro-
logic outcome in 16 patients with intrauterine myelo-
meningocele repair performed at VUMC and found no
improvement in the urinary bladder function when com-
pared with those myelomeningocele patients without
prenatal repair.
Dermoid inclusion cysts and early spinal cord tethering after
fetal surgery for myelomeningocele
Mazzola et al [33] reported that three girls who had
undergone intrauterine myelomeningocele repair at
CHOP suffered from spinal cord tethering and large
dermoid inclusion cysts in infancy.
Neurodevelopmental outcomes
In a study of neurodevelopmental outcomes of 30 chil-
dren at 2 years of age who had undergone intrauterine
myelomeningocele repair at CHOP, Johnson et al [34]
found that 67% of the children had normal cognitive
language and personal–social skills, 20% had mild delays
and 13% had significant delays. They also found that
13 children who had undergone ventriculoperitoneal
shunting scored lower than those with nonshunted
ventriculomegaly.
Perinatal survival and prematurity
In a study of 50 patients with intrauterine myelo-
meningocele repair performed at CHOP, Johnson et al
[29] found perinatal survival in 47 patients (94%), and
the mean age at delivery was 34+3 gestational weeks.
Recurrence Risk of NTDs
Only 5% of NTDs occur in families with a positive family
history, and 95% of NTDs occur spontaneously in women
with no family history [35]. The recurrence risk increases
to 10-fold the population risk when a woman has had
one previous affected pregnancy, doubles for two pre-
vious affected pregnancies and quadruples for three
previous affected pregnancies [35]. Chromosomal ab-
normalities, risk factors, syndromes, disorders and other
etiologies should be considered during counseling on
the recurrence risk of NTDs. Main and Mennuti [36]
reported the following estimated incidence of NTDs
based on specific risk factors in the United States: general
incidence, 1.4–1.6/1,000 live births; women undergoing
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amniocentesis for advanced maternal age, 1.5–3.0/1,000
live births; women with diabetes mellitus, 20/1,000 live
births; women on valproic acid in the first trimester,
10–20/1,000 live births; one sibling with NTD, 15–30/
1,000 live births; two siblings with NTD, 57/1,000 live
births; a parent with NTD, 11/1,000 live births; half
sibling with NTD, 8/1,000 live births; first cousin with
NTD, 10/1,000 live births; other first cousins with NTD,
3/1,000 live births; sibling with severe scoliosis secondary
to multiple vertebral defects, 15–30/1,000 live births;
sibling with occult spina dysraphism, 15–30/1,000 live
births; and sibling with sacrococcygeal teratoma or
hamartoma, ≤ 15–30/1,000 live births. The ACOG [4]
suggested that folic acid supplementation of 400μg/day
is recommended for low-risk women, and folic acid sup-
plementation of 4mg/day is recommended for women at
high risk for NTD or who have had a previous pregnancy
with an NTD. Stevenson et al [37] found a decline in the
prevalence of NTDs from 1.89/1,000 to 0.95/1,000 live
births and fetal deaths in South Carolina during 1992–
1998, and no NTD recurrences in 113 subsequent preg-
nancies to mothers of infants with isolated NTDs, who
took periconceptional folic acid supplementation. They
also reported that the rate of periconceptional folic acid
use among women of childbearing years increased from
8% to 35% during the 6-year project period.
Differential Diagnosis of NTDs Using
Prenatal Ultrasound
Differential diagnosis of NTDs using prenatal ultra-
sound should include sacrococcygeal teratoma, cystic
hygroma, hemangioma, hemangiolymphangioma, scalp
edema/cephalohematoma, epidermal scalp cyst, bran-
chial cleft cyst, dermoid cyst of the anterior fontanelle,
dacryocystocele, epignathus, and cervical teratoma.
Sacrococcygeal teratoma
When cystic myelomeningocele in the lumbosacral re-
gion is diagnosed, a differential diagnosis of sacrococ-
cygeal teratoma should be considered. Lumbosacral
myelomeningocele is usually a symmetric cystic, complex
or solid mass in the lumbosacral region, and may be
associated with ventriculomegaly and lemon or banana
sign on prenatal ultrasound [38]. In contrast, sacro-
coccygeal teratoma is usually a solid mass arising from
the buttocks, often has intrapelvic components, and is
rarely a symmetric cystic mass [38]. Sacrococcygeal ter-
atoma is a germ cell tumor arising from the presacral
area. Sacrococcygeal teratoma has been classified by
the American Academy of Pediatrics Surgical Section
(AAPSS) on the basis of the amount of presacral and
external tumor present, stage and timing of diagnosis,
ease of resection, and malignant potential [39]. Sacro-
coccygeal teratoma is generally exophytic (AAPSS type I),
but may retroperitoneally extend into the pelvis (AAPSS
type II) or abdomen (AAPSS type III). In AAPSS type IV
sacrococcygeal teratoma, the tumor is completely inter-
nal with no external component. The prognosis of fetal
sacrococcygeal teratoma seems to be related to its con-
tent and extent rather than the size of the mass. Diffuse
solid content, high vascularity, extensive intra-abdominal
and intrapelvic hemorrhage may cause vascular steal
from the umbilical artery blood flow to the placenta,
resulting in fetal anemia, high-output cardiac failure,
hydrops fetalis, placentomegaly, and an eclamptic-like
disorder termed “maternal mirror syndrome” consisting
of maternal hypertension, respiratory compromise and
renal impairment. Large sacrococcygeal teratoma may
cause dystocia, traumatic tumor rupture, and hemor-
rhage during vaginal delivery. Prenatal visualization of
the vasculature of fetal sacrococcygeal teratoma can
be made by three-dimensional color power angiogra-
phy [40,41]. The three-dimensional color Doppler ultra-
sound helps the reconstruction of the vasculature,
allowing visualization of the blood flow between the
sacrococcygeal teratoma and fetal circulation [40,41].
Fetal magnetic resonance imaging is useful in provid-
ing a better contrast between the cystic and solid com-
ponent of the tumor, and in delineating the intrapelvic
extent of sacrococcygeal teratoma [41,42].
Cystic hygroma, hemangioma, hemangiolymphangioma,
scalp edema/cephalohematoma, epidermal scalp cyst
and branchial cleft cyst
When occipital encephalocele is diagnosed, a differ-
ential diagnosis of cystic hygroma, hemangioma, hem-
angiolymphangioma, scalp edema/cephalohematoma,
epidermal scalp cyst and branchial cleft cyst should 
be considered. Cystic hygroma or lymphangioma is
composed of large cystic spaces with endothelium-
lined channels of varying dimensions. Congenital cystic
hygroma is caused by anomalous embryologic develop-
ment of the lymphatic system. The advent of ultraso-
nography has made possible the prenatal diagnosis of
congenital cystic hygroma and observation of its pro-
gression in utero [43]. Occipital encephalocele always
has a calvarial defect, usually contains herniated brain
tissues in the sac, can be associated with microcephaly
and hydrocephalus, and is located in the midline [44].
However, cystic hygroma seldom has a bone defect in the
skull unless in association with coexistent encephalo-
cele, contains only fluid in the sac, is associated with
multiple septa, is rarely associated with microcephaly
or hydrocephalus, and is located in the retrolateral
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aspect of the neck [44]. Fetal scalp hemangioma may
prenatally mimic encephalocele [45–49]. Color Doppler
imaging is useful for differentiation of fetal cystic hy-
groma, hemangioma and hemangiolymphangioma, by
demonstrating low-resistance flow and blood vessels
within the hemangioma and hemangiolymphangioma.
Hemangiolymphangioma often presents on prenatal
ultrasound as a heterogeneous cystic and solid mul-
tiloculated mass with a propensity for rapid growth
and invasion into adjacent tissues. Winter et al [47]
reported the prenatal sonographic diagnosis of scalp
edema/cephalohematoma mimicking an encephalocele
at 31 gestational weeks, with no flow within the mass
on color Doppler ultrasound. Shahabi and Busine [48]
reported the prenatal sonographic diagnosis of an epi-
dermal scalp cyst simulating an encephalocele at 17
gestational weeks with no associated ventriculomegaly.
Tsai et al [50] reported the prenatal imaging findings
of fetal branchial cleft cyst presenting as a nuchal cyst
with homogeneous contents and no septa. Branchial
cleft cyst is believed to be the result of incomplete in-
volution of the branchial apparatus, and the lack of any
solid elements or septa can be used to differentiate
branchial cleft cyst from cervical teratoma [50–52].
Dermoid cyst of the anterior fontanelle and
dacryocystocele
When frontal encephalocele is diagnosed, a differen-
tial diagnosis of dermoid cyst of the anterior fontanelle
and dacryocystocele should be considered. Dermoid
cyst of the anterior fontanelle may present with fluid in
the mass and the appearance of a bony defect [38,53].
Dacryocystocele or lacrimal duct cyst is a small sono-
lucent cyst located inferomedially to the orbit and is
caused by obstruction of the proximal and distal
lacrimal ducts [54].
Epignathus and cervical teratoma
When basal encephalocele is diagnosed, a differential
diagnosis of epignathus should be considered. Epig-
nathus is a rare teratoma of the oropharynx and usu-
ally originates from the base of the skull in the posterior
nasopharynx involving the hard palate or sphenoid bone
[55]. Two- and three-dimensional ultrasound scans are
useful in the prenatal investigation of fetal epignathus,
by detailed assessments of the craniofacial structural
abnormalities of the fetus and the vasculature of the
tumor [56]. Cervical teratoma presents as a solid or
mixed solid-cystic tumor that is located in the anterior
or anterolateral neck [54]. Cervical teratoma can cause
airway obstruction and may call for the need of tra-
cheostomy or ex utero intrapartum treatment procedure
during delivery [57–59].
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